The stock dropped 13% to $5.89 during Friday trading, erasing recent momentum. Despite the sharp sell-off, the equity remains up 2% over the past 12 months as investors weigh the company’s long-term growth against its immediate financial performance.

Earnings vs. Estimates

The company’s financial results fell just short of analyst projections. According to data polled by FactSet, markets were anticipating a net income of $4,500, or roughly one cent per share. Instead, Ardelyx recorded a net loss of $407,000, resulting in a breakeven result on a per-share basis.

While the loss was marginal in absolute terms, the missed earnings target triggered a swift reaction from investors who had priced in a more robust transition to profitability. The biopharmaceutical developer continues to navigate a volatile market for commercial-stage healthcare firms as it seeks to stabilize its balance sheet.